首页|胃肠道微针用于生物大分子药物口服递送研究进展

胃肠道微针用于生物大分子药物口服递送研究进展

扫码查看
生物大分子药物因具有高靶向性、剂量小、安全性和生物活性高等独特优势而越来越多地被用于多种疾病的治疗。但同时由于其分子质量大、亲水性强及胃肠道稳定性差等缺点,加之胃肠道复杂的生理屏障,导致生物大分子口服生物利用度极低。胃肠道微针作为一种新型主动药物递送技术,因其能够直接突破胃肠道屏障而实现药物的定位递送、高效吸收而在生物大分子药物口服递送方面具有巨大的潜力。本综述围绕胃肠道微针的驱动及设计策略、制备方法及其口服递送生物大分子药物的应用等方面进行了总结归纳,并对该技术目前存在的局限性及发展趋势进行了分析,以促进胃肠道微针的后续研发和临床转化,为生物大分子的口服给药提供高效、安全的新策略。
Advances in the study of gastrointestinal microneedles for oral delivery of biomacromolecule drugs
Biomacromolecule drugs have been increasingly used in clinical practice due to their distinct advantages,including precise targeting,small dose,high safety and activity.However,owing to their high molecular weight,strong hydrophilicity,and poor stability in the gastrointestinal tract,the oral bioavailability of the biomacromolecule drugs remains extremely poor.As a novel and innovative technology for active drug delivery,gastrointestinal microneedles hold immense potential in the oral delivery of biomacromolecule drugs because of their low-invasive nature and high permeation enhancement effects.This review primarily summarizes the actuating force,design strategies,fabrication techniques,and applications of gastrointestinal microneedles for the oral delivery of biomacromolecule drugs.Additionally,the challenges and further perspectives in the development this technology are presented,aiming to promote the subsequent research and clinical translation of gastrointestinal microneedles,and to provide a new efficient and safe strategy for oral delivery of biomacromolecule drugs.

gastrointestinal microneedlebiomacromoleculeoral drug deliverybioavailability

冯嘉惟、叶小风、张奇镔、魏颖慧

展开 >

浙江中医药大学药学院,浙江杭州 310000

胃肠道微针 生物大分子 口服递送 生物利用度

国家自然科学基金资助项目

82374047

2024

药学学报
中国药学会 中国医学科学院药物研究所

药学学报

CSTPCD北大核心
影响因子:1.274
ISSN:0513-4870
年,卷(期):2024.59(7)
  • 51